Blog Read the latest perspectives from our team of subject matter experts and others Leading Health Plans Are Adopting AI to Transform Network OperationsHealth plans are under growing pressure to improve provider directory accuracy, accelerate roster processing, and prepare for a rapidly evolving regulatory environment. Leading organizations are responding by applying AI across… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology Drug DevelopmentPatient RepresentationThe ABCs (and Ds) of Clinical Trial InclusionWhen the FDA mandated guidelines earlier this year for broader clinical trial inclusion, it brought a long-standing challenge in pharma and life sciences into the spotlight. Here, Alexandra Moens, H1’s… Continue reading → Read the articleno Drug DevelopmentKOL EngagementPatient RepresentationA New Reflection on Pharma, Research, and Patient CarePharma has long existed in elevated, prestigious academic institutions: ivory towers of reputable and revered centers of excellence famous for disseminating the latest in clinical research and medical breakthroughs.… Continue reading → Read the article Drug DevelopmentKOL EngagementH1 Announces Partnership with Society for Clinical Research SitesThe Society for Clinical Research Sites (SCRS) announced today that H1, a pioneer in creating connected ecosystems where data, people, research, and clinical trial intelligence come together to drive the… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataThe Evolution of H1’s Core ValuesI remember it clearly. Me, Ian – our co-founder and a handful of brave individuals who would become the first H1 employees, sitting around a table writing down the values… Continue reading → Read the article Drug DevelopmentPatient RepresentationInclusive Healthcare Starts with Medical AffairsBecause they serve as the bridge between research and commercial functions of life sciences companies, medical affairs can drive equity in clinical trials by proactively engaging with a diverse set… Continue reading → Read the article KOL EngagementA Case Study on Global KOL EngagementIn a recent issue of Nature that traced the origins of key opinion leaders in pharma back to a Pfizer launch in the mid-1950s, the article tracked the evolution and… Continue reading → Read the article«‹10111213141516›»
